Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Nemtabrutinib Formulations in Healthy Males
NCT06586671Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nemtabrutinib in hematological malignancy (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity up to 2 weeks and Maximum Plasma Concentration up to 2 weeks. Started Aug 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT06586671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586671.